Jurij Fürst

Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Steven Simoens, Brian Godman, Renata Curi Hauegen, 2019, Applied Health Economics and Health Policy.

Pricing of oral generic cancer medicines in 25 European countries; findings and implications

Steven Simoens, Brian Godman, Guenka Petrova, 2019, Generics and Biosimilars Initiative Journal.

Personalizing health care: feasibility and future implications

Jan Jones, Steven Simoens, Fredrik Nilsson, 2013, BMC Medicine.

Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries

Steven Simoens, Bogdan Asanin, Vincent Hargaden, 2018, Front. Pharmacol..

Policies for biosimilar uptake in Europe: An overview

Steven Simoens, Isabelle Huys, Brian Godman, 2017, PloS one.

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications

Brian Godman, Samantha Alvarez-Madrazo, Stephen Campbell, 2014, Front. Pharmacol..

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Andy Gray, Brian Godman, Ilse Truter, 2015, Expert review of clinical pharmacology.

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications

Panos Kanavos, Brian Godman, Guenka Petrova, 2017, PharmacoEconomics (Auckland).

Initiatives among Authorities to Improve the Quality and Efficiency of Prescribing and the Implications

Brian Godman, Ilse Truter, Andrew Martin, 2016 .